Science Advisory Committee

Dr. Gregory Cote

Gregory Cote

Dr. Gregory Cote is a medical oncologist at the Massachusetts General Hospital Cancer Center in the Henri and Belinda Termeer Center for Targeted Therapies (Phase I), the Center for Sarcoma and Connective Tissue Oncology, and the Stephan L. Harris Center for Chordoma Care. His primary research interest is in developing novel agents for sarcomas through early phase clinical trials and translational laboratory collaborations with a focus on the DNA-Damage Response pathway, epigenetics, immunotherapy, and chemotherapy resistance. He is the primary investigator of a clinical trial of eribulin in angiosarcoma and epithelioid hemangioendothelioma.  Dr. Cote received his MD and Ph.D. from Boston University School of Medicine, completed his residency at Massachusetts General Hospital, and his fellowship at combined Partners/Dana-Farber Cancer Institute program.


Dr. Michael Wagner

Dr. Michael Wagner
Michael Wagner, MD is an Assistant Professor of Medicine at the University of Washington and an Assistant Member in the Clinical Research Division at the Fred Hutchinson Cancer Research Center (FHCRC). After graduating from Harvard University with a medical degree, Dr. Wagner completed his residency at Mt. Sinai Hospital in New York and a medical oncology fellowship at the University of Texas MD Anderson Cancer Center. Dr. Wagner has received numerous awards, including the Conquer Cancer Foundation of ASCO Young Investigator Award and QuadW Foundation-AACR Fellowship for Clinical/Translational Research for his research on sarcoma. His research interests include angiosarcoma and other vascular sarcomas, and bone and soft tissue sarcomas.


Dr. Breelyn A. Wilky, MD

Breelyn Wilky
Dr. Breelyn A. Wilky, MD is a sarcoma medical oncologist and clinical trialist with research interests in immunotherapy, targeted therapy and precision medicine, and early phase drug development. She has recently joined the University of Colorado School of Medicine as Associate Professor, where she is a member of the Sarcoma and Phase I Programs. She works to expand the portfolio of investigator-initiated clinical trials, and advance immunotherapy and adoptive cellular therapy for solid tumors. As the Director of Sarcoma Translational Research, she studies the tumor and immune microenvironment of sarcomas in the laboratory, to identify new drugs that boost the immune system for future clinical trials in sarcoma.

Dr. Wilky received her undergraduate degree in Biology and Music from Bates College in Lewiston, Maine, and attended medical school at the University of Medicine and Dentistry of New Jersey – Robert Wood Johnson Medical School in Piscataway, New Jersey (now Rutgers Medical School.) She received her MD with Distinction in Research. She then completed the Osler internship and residency in Internal Medicine at The Johns Hopkins Hospital in Baltimore, Maryland, and stayed on to complete her fellowship in Medical Oncology. Her honors and awards include election to the Alpha Omega Alpha Honor Medical Society, an ASCO/Conquer Cancer Foundation Young Investigator Award in 2012, the 2017 Outstanding Clinical Researcher of the Year at Sylvester Comprehensive Cancer Center at the University of Miami, and most recently the recipient of an American Cancer Society Mentored Research Scholar Grant to further her research in understanding the role of the immune system in fighting sarcomas.